Earlier this month the FDA announced a major recall of prescription blood pressure and heart drugs which contain the active ingredient valsartan. You can expect a large number of valsartan lawsuits to follow.
Valsartan is an active ingredient that is widely used in a number of brand name and generic drugs used to treat hypertension and heart failure. It was recently discovered that when valsartan is manufactured in a certain way it can contain a dangerous impurity called N-nitrosodimethylamine (NMDA).
NMDA is a known human carcinogen. The valsartan medications containing the dangerous NMDA impurity have been linked to a specific pharmaceutical ingredient distributed by a Chinese company — Zhejiang Huahai Pharmaceuticals. Zhejiang Huahai was manufacturing the contaminated valsartan component and selling it to several U.S. pharmaceutical companies including Teva Pharmaceuticals Ltd. and Solco Healthcare. Zhejiang Huahai discovered NMDA impurities in its product which eventually led to the FDA recall.